Prospects for the Use OF Rivaroxaban in the Treatment OF Patients with Chronic Ischemic Heart Disease
A. K. (Abdushukurova) RustamovnaDepartment of Internal Medicine No.1 , Samarkand State Medical University , Samarkand , Uzbekistan
ABI
Abstract
The review is devoted to the analysis of ways to influence hemostasis in order to improve the prognosis of patients with chronic coronary heart disease (CHD). The results of the most significant randomized clinical trials evaluating the effectiveness and safety of dual antiplatelet therapy in the treatment of patients with chronic ischemic heart disease are discussed. The use of rivaroxaban in addition to acetylsalicylic acid (ASA) to reduce the risk of cardiovascular events in patients with chronic ischemic heart disease is justified.
Citations and references
Cited by 00 references